Milestone will present a moderated poster presentation at the American College of Cardiology annual meeting, to be held March 29th to 31st, 2025 in Chicago, Illinois. “This presentation highlights the potential ability of etripamil to successfully convert multiple episodes of Paroxysmal Supraventricular Tachycardia to restore normal sinus rhythm. Further, the data showed that conversion of earlier episodes was predictive of conversion in subsequent ones,” said David Bharucha, CMO. “These new data support the opportunity to use etripamil, if approved, for successive PSVT episodes underscoring a potentially positive impact on patients’ experience and quality of life, in line with Milestone’s commitment to providing a convenient and effective therapeutic option for PSVT.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals: Buy Rating Backed by Promising FDA Approval and Market Expansion Prospects
- Optimistic Buy Rating for Milestone Pharmaceuticals Driven by Strategic Plans and Financial Strength
- Milestone Pharmaceuticals’ SEC Exemptions: Balancing Reduced Disclosure with Investor Confidence Risks
- Milestone Pharmaceuticals Eyes FDA Approval for CARDAMYST
- Milestone Pharmaceuticals Awaits FDA Decision on CARDAMYST, Prepares for Mid-2025 Launch